3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Interventions
Paclitaxel
6
liposomal doxorubicin
4
Carboplatin
4
Topotecan
3
Drug Therapy
3
Gemcitabine
2
Doxorubicin
2
Bevacizumab
2
1-dodecylpyridoxal
2
trametinib
1
saracatinib
1
pertuzumab
1
pembrolizumab
1
pegfilgrastim
1
olaparib
1
masitinib
1
dabrafenib
1
cyclopropapyrroloindole
1
cobimetinib
1
cediranib
1
atezolizumab
1
aflibercept
1
abagovomab
1
Vemurafenib
1
Trastuzumab
1
Taxes
1
Poly(ADP-ribose) Polymerase Inhibitors
1
Neoadjuvant Therapy
1
NP-G2-044
1
Magnetic Resonance Spectroscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Ovarian Neoplasms
×
abagovomab
×
Clear all
NCT00418574
2011-11-24
MIMOSA
Menarini Group
Phase 2/3
Terminated
888 enrolled
17 charts